The National Healthcare Security Administration is soliciting public opinions on the "Renewal Rules for Negotiated Drugs" and the "Bidding Rules for Non-Exclusive Drugs" today. According to an industry analyst, the new rules mainly have three changes: 1. Inclusion in the regular catalog. 2. The price reduction in this round of negotiations will take into account the previous reduction, which will be more moderate than before. 3. The renewal threshold has been raised. Exceeding market expectations, overall it is favorable for innovative drugs.